NxStage Releases New Patient Data; Remains Committed to Top Line Growth

NxStage Medical, a Lawrence, MA company that makes dialysis systems, has released new end-stage renal-disease (ESRD) patient data. The information was derived from a registry of NxStage patients who undergo hemodialysis at home using the company’s System One.

Compared to the conventional regimen of thrice-a-week therapy at a dialysis center, survival and transplant rates were significantly higher among the NxStage patient population. NxStage patients experienced 50 percent-plus reduction in expected mortality as compared to the overall U.S. hemodialysis patient population.

Survival is the “gold standard” of clinical outcomes. Multiple observational, retrospective studies have been published demonstrating 45% to 61% reductions in mortality with home and/or daily dialysis (a randomized, controlled trial of survival of the daily hemodialysis population is unlikely to occur, given study size and enrollment limitations).

Geographic data shows NxStage is doing a good job breaking down barriers to initiating System One use; 92% of the U.S. dialysis population resides within 60 miles of a center offering NxStage home hemodialysis training, and nearly 80% are within 30 miles.

At the end of the first quarter 2008, NxStage was working with 355 dialysis centers to provide home hemodialysis therapy to 2,481 end-stage renal disease patients.

This compares to 200 centers and 1,295 patients at the end of the first quarter of 2007. The company expects to end the year with between 3,100 and 3,500 patients using its System One device.

NxStage has yet to recover from a disappointing earnings report that sent shares plummeting to the four-dollar range. Though revenues grew nearly four-fold to $31.0 million in Q1 (compared to $8.4 million in the first quarter of 2007), NxStage’s loss widened to $13.9 million from $12 million. The cost of sales grew to $27 million from $10 million; operating expenses rose 54% to $17.2 million, year-over-year.

The company remains committed to top line growth. And according to Jeffrey Burbank, President and CEO of NxStage, “[We’re] confident that home daily hemodialysis is a significant market opportunity in particular, over the long-term because of its clear patient benefits.”

Second quarter results are due August 5th.

  1. » NxStage Medical Signs Long-Term Supply Agreement with Renal Advantage | OneMedPlace » Archive

    on October 21, 2008

    […] Previously:  NxStage Remains Committed to Top Line Growth  […]


  2. Stuart Smith

    on December 29, 2008

    Why is the cost of using the 5 days per week NxStage system more then center based thrice-weekly dialysis? This does not seem right since I provide the treatments with no compensation from the center?

    The center “doesn’t pay me to do the treatments” but charges more for each treatment support only then when “they do” all the work at the in-center treatments.

    I give my family member treatments, I am compensated at minimum wage by California DHS (dept of health services) which may cut the program in the near future.

    Why does the dialysis center charge more for me giving the treatments using NxStage then when they treat in center?

    Redundant but a real concern in this matter.

    If the treatments saved money as will as extend life more folks may get on board.

    If NxStage system one home treatment providers were compensated through the dialysis center at a living wage this would open up more oppertunity for more folks to recieve dialyisis more comfortable at home.

    It seems money and libility is ruining healthcare once more.

    Thanks for your time,
    Stuart Smith.


Add Your Comments